Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 12/20 | 0.59 |
| ▸ | BCL2 | P10415 | 14/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855685 | 0.94 | BCL2L1 (0.58) | BCL2L1BCL2MCL1 | |
| SCHEMBL14655243 | 0.91 | MAPT (0.59) | BCL2L1BCL2MCL1MAPTMAPK1 | |
| SCHEMBL30528147 | 0.90 | BCL2L1 (0.62) | BCL2L1BCL2MCL1 | |
| SCHEMBL30112966 | 0.90 | MAPT (0.51) | BCL2L1BCL2MCL1MAPTMAPK1 | |
| SCHEMBL29404300 | 0.90 | BCL2 (0.55) | BCL2L1BCL2MCL1MAPT | |
| SCHEMBL30112869 | 0.90 | BCL2L1 (0.58) | BCL2L1BCL2MCL1MAPTMAPK1 | |
| SCHEMBL29644474 | 0.90 | BCL2L1 (0.54) | BCL2L1BCL2MCL1MAPTMAPK1 | |
| SCHEMBL30622006 | 0.90 | BCL2L1 (0.54) | BCL2L1BCL2MCL1MAPTMAPK1 | |
| SCHEMBL18392434 | 0.90 | BCL2L1 (0.53) | BCL2L1BCL2MCL1MAPT | |
| SCHEMBL20412271 | 0.90 | BCL2L1 (0.53) | BCL2L1BCL2MCL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367287-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2025-12-04 | — | — | US | claimed |
| CN-119584963-A | Methods of treating multiple myeloma using BCL-2 inhibitors | 百济神州(苏州)生物科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | claimed |
| CN-119384276-A | Methods of treating myelogenous malignancies using BCL-2 inhibitors | 百济神州瑞士有限责任公司 | 2025-01-28 | — | — | CN | claimed |
| CN-119053610-A | 1,3,4, 7-Tetrahydro-2H-pyrrolo [3',2':5,6] pyrido [2,3-b ] [1,4] oxazepine Bcl-2 inhibitors | 艾伯维公司 | 2024-11-29 | — | — | CN | claimed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | claimed |
| US-20240277838-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | GENENTECH, INC. (US) | 2024-08-22 | — | — | US | claimed |
| US-20240122932-A1 | Methods of Treating B-Cell Malignancy Using Bcl-2 Inhibitor | BEIGENE SWITZERLAND GMBH (CH) | 2024-04-18 | — | — | US | claimed |
| CN-117835974-A | Methods of treating B cell malignancies using BCL-2 inhibitors | 百济神州有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-116270660-A | Bcl-2/Bcl-xl inhibitor-containing composition and preparation method and application thereof | 广州麓鹏制药有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-111511748-B | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-111448198-B | Condensed heterocyclic derivatives as Bcl-2 inhibitors for the treatment of neonatal diseases | 广州麓鹏制药有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | claimed |
| CN-115484933-A | Hot melt extrusion solid dispersions containing BCL2 inhibitors | 广州麓鹏制药有限公司 | 2022-12-16 | — | — | CN | claimed |
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | claimed |
| EP-2376197-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | claimed |
| EP-2376480-A2 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | claimed |
| WO-2010065824-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | claimed |
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2L1 2/4885BCL2 1/4885MCL1 13/4885 |
| US-20240277838-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | ERBB2, BAK1, BCL2L2 | BCL2L1 6/4885BCL2 4/4885MCL1 22/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | BCL2L1 2/4885BCL2 1/4885MCL1 13/4885 |
| US-20250367287-A1 | COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR | ERBB2, BAK1, BCL2L2 | BCL2L1 6/4885BCL2 4/4885MCL1 22/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | BCL2L1 4/4885BCL2 2/4885MCL1 14/4885 |
| US-20240122932-A1 | Methods of Treating B-Cell Malignancy Using Bcl-2 Inhibitor | BCL3, BCL6, BTK | BCL2L1 14/4885BCL2 8/4885MCL1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.